Xiangzhe Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiangzhe Kong has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Yang Liu
Department of Computer Science and Technology, Tsinghua University, Beijing, China
5 shared publications - Jianzhu Ma
Department of Electronic Engineering, Tsinghua University, Beijing, China
4 shared publications - Rui Jiao
Department of Computer Science and Technology, Tsinghua University, Beijing, China
4 shared publications Haowei Lin
Institute for Artificial Intelligence, Peking University, Beijing, China
3 shared publicationsRuihan Guo
Helixon US Inc., New York, USA
3 shared publicationsWenbing Huang
Gaoling School of Artificial Intelligence, Renmin University of China, Beijing, China
3 shared publications
Latest Publications
- Open Access
Programming Biomolecular Interactions with All-Atom Generative Model
Biomolecular interactions lie at the core of cellular life, spanning diverse molecular modalities from small molecules to nucleic acids and proteins. Nevertheless, design strategies remain separated despite shared physicochemical principles of molecular recognition. Here we present AnewOmni, a unified generative framework trained on more than 5 million biomolecular complexes, that enables transferable molecular design across molecular scales by assembling chemically meaningful building blocks at atomic resolution. We further introduce programmable graph prompts to support user-defined chemical, topological, and geometric steering during generation, exploring hybrid and unconventional chemistries beyond canonical structures. We demonstrate that transferable learning of interaction patterns and physical constraints across molecular modalities is possible, via an atom-to-block latent space capturing both atomic details and structural priors. The framework successfully designed small molecules, peptides, and nanobodies targeting the challenging KRAS G12D switch II pocket, as well as orthosteric peptides and allosteric small-molecule inhibitors for PCSK9 in the absence of known binding site, achieving 23%-75% success with only low-throughput validation, bypassing modality-specific high-throughput screening. AnewOmni is the first to succeed in functional molecular design across all scales, from small chemical entities to large biologics, and represents a stepstone towards general molecular reasoning engines, advocating a generative foundation model for biomolecular interactions to enter regimes where data and human intuition remain limited.
Open AccessProgramming Biomolecular Interactions with All-Atom Generative Model
Biomolecular interactions lie at the core of cellular life, spanning diverse molecular modalities from small molecules to nucleic acids and proteins. Nevertheless, design strategies remain separated despite shared physicochemical principles of molecular recognition. Here we present AnewOmni, a unified generative framework trained on more than 5 million biomolecular complexes, that enables transferable molecular design across molecular scales by assembling chemically meaningful building blocks at atomic resolution. We further introduce programmable graph prompts to support user-defined chemical, topological, and geometric steering during generation, exploring hybrid and unconventional chemistries beyond canonical structures. We demonstrate that transferable learning of interaction patterns and physical constraints across molecular modalities is possible, via an atom-to-block latent space capturing both atomic details and structural priors. The framework successfully designed small molecules, peptides, and nanobodies targeting the challenging KRAS G12D switch II pocket, as well as orthosteric peptides and allosteric small-molecule inhibitors for PCSK9 in the absence of known binding site, achieving 23%-75% success with only low-throughput validation, bypassing modality-specific high-throughput screening. AnewOmni is the first to succeed in functional molecular design across all scales, from small chemical entities to large biologics, and represents a stepstone towards general molecular reasoning engines, advocating a generative foundation model for biomolecular interactions to enter regimes where data and human intuition remain limited.
- Top Cited PapersOpen Access
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
An equivariant pretrained transformer for unified 3D molecular representation learning
Pretraining on a large number of unlabeled 3D molecules has showcased superiority in various scientific applications. However, prior efforts typically focus on pretraining models in a specific domain, missing the opportunity to leverage cross-domain knowledge. To mitigate this gap, we introduce Equivariant Pretrained Transformer, an all-atom foundation model that can be pretrained from multiple domain 3D molecules. Built upon an E(3)-equivariant transformer, the model learns both atom-level interactions and graph-level structural features ( e.g . residuals in proteins), allowing it to generalize across diverse tasks. The model achieves strong gains in ligand binding affinity prediction, while also performing competitively in predicting properties of proteins and small molecules. We further show that the model can help identify potential antiviral compounds against the main protease of the COVID-19 virus, and validate promising candidates through computational and experimental studies.
- 10 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessAn equivariant pretrained transformer for unified 3D molecular representation learning
Pretraining on a large number of unlabeled 3D molecules has showcased superiority in various scientific applications. However, prior efforts typically focus on pretraining models in a specific domain, missing the opportunity to leverage cross-domain knowledge. To mitigate this gap, we introduce Equivariant Pretrained Transformer, an all-atom foundation model that can be pretrained from multiple domain 3D molecules. Built upon an E(3)-equivariant transformer, the model learns both atom-level interactions and graph-level structural features ( e.g . residuals in proteins), allowing it to generalize across diverse tasks. The model achieves strong gains in ligand binding affinity prediction, while also performing competitively in predicting properties of proteins and small molecules. We further show that the model can help identify potential antiviral compounds against the main protease of the COVID-19 virus, and validate promising candidates through computational and experimental studies.
- Open Access
SpecLig: Energy-Guided Hierarchical Model for Target-Specific 3D Ligand Design
Structure-based generative models often optimize single-target affinity with ignorance of specificity, resulting in the generation of high-affinity candidates that exhibit promiscuous binding across unrelated targets. This decoupling of affinity and specificity not only compromises therapeutic efficacy but also elevates off-target risks that constrain translational potential. Therefore, we introduce SpecLig, a unified structure-based framework that jointly generates small molecules and peptides with improved target affinity and specificity. SpecLig represents a complex as a block-based graph, combining a hierarchical SE(3)-equivariant variational autoencoder with an energy-guided geometric latent-diffusion model. Chemical priors derived from block–block contact statistics are explicitly incorporated, biasing generation towards pocket-complementary fragment combinations. We benchmark SpecLig on peptide and small-molecule tasks using standard public datasets and propose precision/breadth testing paradigms to quantify specificity. Across multiple evaluations, ligand candidates generated by SpecLig usually bind to the target pocket with high specificity and affinity while maintaining competitive advantages in other attributes. Ablations indicate that both hierarchical representation and energy guidance contribute to success. Finally, we present multiple real applications that demonstrate how SpecLig improves ligands in natural complexes to mitigate potential off-target risks. SpecLig, therefore, provides a practical route to prioritize higher-specificity designs for downstream experimental validation. The codes are available at: https://github.com/CQ-zhang-2016/SpecLig .
Open AccessSpecLig: Energy-Guided Hierarchical Model for Target-Specific 3D Ligand Design
Structure-based generative models often optimize single-target affinity with ignorance of specificity, resulting in the generation of high-affinity candidates that exhibit promiscuous binding across unrelated targets. This decoupling of affinity and specificity not only compromises therapeutic efficacy but also elevates off-target risks that constrain translational potential. Therefore, we introduce SpecLig, a unified structure-based framework that jointly generates small molecules and peptides with improved target affinity and specificity. SpecLig represents a complex as a block-based graph, combining a hierarchical SE(3)-equivariant variational autoencoder with an energy-guided geometric latent-diffusion model. Chemical priors derived from block–block contact statistics are explicitly incorporated, biasing generation towards pocket-complementary fragment combinations. We benchmark SpecLig on peptide and small-molecule tasks using standard public datasets and propose precision/breadth testing paradigms to quantify specificity. Across multiple evaluations, ligand candidates generated by SpecLig usually bind to the target pocket with high specificity and affinity while maintaining competitive advantages in other attributes. Ablations indicate that both hierarchical representation and energy guidance contribute to success. Finally, we present multiple real applications that demonstrate how SpecLig improves ligands in natural complexes to mitigate potential off-target risks. SpecLig, therefore, provides a practical route to prioritize higher-specificity designs for downstream experimental validation. The codes are available at: https://github.com/CQ-zhang-2016/SpecLig .
- Open Access
- 27 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (7) , 1
Author Correction: Peptide design through binding interface mimicry with PepMimic
- 27 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (7) , 1
Open AccessAuthor Correction: Peptide design through binding interface mimicry with PepMimic
- 1 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (7) , 1-16
Peptide design through binding interface mimicry with PepMimic
Peptides offer advantages for targeted therapy, including oral bioavailability, cellular permeability and high specificity, setting them apart from conventional small molecules and biologics. Here we develop an artificial intelligence algorithm, PepMimic, to transform a known receptor or an existing antibody of a target into a short peptide binder by mimicking the binding interfaces between targets and known binders. We apply PepMimic to drug targets PD-L1, CD38, BCMA, HER2 and CD4. Surface plasmon resonance imaging results show that 8% of the peptides exhibit dissociation constant (KD) values at the 10−8 M level, and 26 peptides achieving KD values as low as 10−9 M, substantially higher than random library screening conducted under identical conditions. We apply PepMimic to target proteins lacking available binders by first using existing algorithms to design protein binders, followed by designing peptide through simulating these artificial interfaces. We extensively validate the top-ranked peptides using tail vein injections in breast, myeloma and lung tumour mouse models. Experimental results demonstrate effective membrane binding and highlight their strong potential for clinical diagnostic imaging and targeted therapeutic applications.
- 1 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (7) , 1-16
Peptide design through binding interface mimicry with PepMimic
Peptides offer advantages for targeted therapy, including oral bioavailability, cellular permeability and high specificity, setting them apart from conventional small molecules and biologics. Here we develop an artificial intelligence algorithm, PepMimic, to transform a known receptor or an existing antibody of a target into a short peptide binder by mimicking the binding interfaces between targets and known binders. We apply PepMimic to drug targets PD-L1, CD38, BCMA, HER2 and CD4. Surface plasmon resonance imaging results show that 8% of the peptides exhibit dissociation constant (KD) values at the 10−8 M level, and 26 peptides achieving KD values as low as 10−9 M, substantially higher than random library screening conducted under identical conditions. We apply PepMimic to target proteins lacking available binders by first using existing algorithms to design protein binders, followed by designing peptide through simulating these artificial interfaces. We extensively validate the top-ranked peptides using tail vein injections in breast, myeloma and lung tumour mouse models. Experimental results demonstrate effective membrane binding and highlight their strong potential for clinical diagnostic imaging and targeted therapeutic applications.
- Open Access
Peptide Design through Binding Interface Mimicry
Peptides offer distinct advantages for targeted therapy, including oral bioavailability, cellular permeability, and high specificity, which set them apart from conventional small molecules and biologics. In this work, we developed an AI algorithm, named PepMimic, to transform a known protein receptor or an existing antibody of a target into a short peptide drug by mimicking the binding interfaces between targets and known binders. The structural root mean square deviation and interface DockQ with reference binders were 61% and 75% better than the best existing methods on the PepBench datasets. We then applied this novel peptide-design methodology to five drug targets: PD-L1, CD38, BCMA, HER2, and CD4. SPRi results show that 8% of the peptides exhibited dissociation constant (K D ) values at the 10 -8 M level, and 26 peptides achieving K D values as low as 10 -9 M. This success rate was 20,000 times higher than that observed in a random library screening conducted under identical conditions. PepMimic was applied to target proteins lacking available binders by first utilizing AI algorithms to design protein binders, followed by the generation of peptides through simulation of these artificial interfaces. The top-ranked peptides underwent extensive cellular validation and in vivo testing through tail vein injections in breast, myeloma, and lung tumor mouse models. Experimental results demonstrated effective membrane binding and highlighted the strong potential of these peptides for clinical diagnostic imaging and targeted therapeutic applications.
Open AccessPeptide Design through Binding Interface Mimicry
Peptides offer distinct advantages for targeted therapy, including oral bioavailability, cellular permeability, and high specificity, which set them apart from conventional small molecules and biologics. In this work, we developed an AI algorithm, named PepMimic, to transform a known protein receptor or an existing antibody of a target into a short peptide drug by mimicking the binding interfaces between targets and known binders. The structural root mean square deviation and interface DockQ with reference binders were 61% and 75% better than the best existing methods on the PepBench datasets. We then applied this novel peptide-design methodology to five drug targets: PD-L1, CD38, BCMA, HER2, and CD4. SPRi results show that 8% of the peptides exhibited dissociation constant (K D ) values at the 10 -8 M level, and 26 peptides achieving K D values as low as 10 -9 M. This success rate was 20,000 times higher than that observed in a random library screening conducted under identical conditions. PepMimic was applied to target proteins lacking available binders by first utilizing AI algorithms to design protein binders, followed by the generation of peptides through simulation of these artificial interfaces. The top-ranked peptides underwent extensive cellular validation and in vivo testing through tail vein injections in breast, myeloma, and lung tumor mouse models. Experimental results demonstrated effective membrane binding and highlighted the strong potential of these peptides for clinical diagnostic imaging and targeted therapeutic applications.